Table 2. Comparisons between female and male with and without IHD.
| Non-IHD | IHD | |||||
| Female (n = 144) | Male (n = 283) | P-Value | Female (n = 246) | Male (n = 1,415) | P-Value | |
| Age (yrs ± SD) | 67.5±13.5 | 60.9±12.3 | P<0.001 | 70.4±10.2 | 64.4±10.3 | P<0.001 |
| Body mass index (kg/m2 ± SD) | 21.9±3.2 | 23.7±3.6 | P<0.001 | 23.0±3.5 | 24.5±3.4 | P<0.001 |
| Current smoker (%) | 8.3 | 28.6 | P<0.001 | 12.6 | 25.1 | P<0.001 |
| Current+past smoker (%) | 19.4 | 70.7 | P<0.001 | 28.5 | 77.0 | P<0.001 |
| Hypertension (%) | 66.0 | 64.0 | NS | 77.6 | 76.3 | NS |
| Diabetes Mellitus (%) | 27.1 | 29.7 | NS | 42.7 | 45.5 | NS |
| Dyslipidemia (%) | 43.1 | 47.0 | NS | 74.0 | 76.3 | NS |
| s-Cr (mg/dl ± SD) | 1.6±2.5 | 1.6±2.3 | P<0.001 | 1.5±2.3 | 1.6±2.3 | P<0.001 |
| HbA1c (% ± SD) | 5.7±1.1 | 5.8±1.1 | NS | 5.9±0.8 | 6.1±1.1 | P<0.05 |
| BNP (pg/ml ± SD) | 319.5±650.4 | 305.5±650.9 | P<0.05 | 303.2±668.2 | 132.3±327.4 | P<0.001 |
| HD & CAPD (%) | 13.2 | 9.5 | NS | 13.0 | 8.7 | P<0.05 |
| LVEF (% ± SD) | 59.3±12.3 | 54.4±15.1 | P<0.001 | 59.5±11.6 | 57.4±10.7 | P<0.01 |
| Heart rate (beat/min ± SD) (At LVG) | 73.3±14.0 | 74.4±17.6 | NS | 72.5±14.3 | 70.3±13.4 | P<0.05 |
| LVEDP (mmHg ± SD) (At Pre LVG) | 16.4±7.0 | 16.6±7.3 | NS | 16.1±6.9 | 15.5±6.1 | NS |
| LVESVI (ml/m2 ± SD) | 31.7±19.8 | 39.0±27.2 | P<0.01 | 27.3±17.0 | 29.1±16.2 | NS |
| Prior myocardial infarction (%) | 0 | 0 | 35.8 | 38.9 | NS | |
| Prior PCI (%) | 0 | 0 | 35.8 | 46.1 | P<0.01 | |
| Prior CABG | 0 | 0 | 15.9 | 12.0 | NS | |
| Coronary spastic angina | 0 | 0 | 12.6 | 7.8 | P<0.05 | |
| Prior valve repair (%) | 7.6 | 3.5 | NS | 1.6 | 0.5 | P<0.05 |
| Valvular heart disease (%) | 38.2 | 26.1 | P = 0.01 | 6.9 | 2.8 | P = 0.001 |
| Congenital heart disease (%) | 8.3 | 3.5 | P<0.05 | 0.4 | 0.4 | NS |
| Cardiomyopathy (%) | 20.8 | 23.7 | NS | 3.3 | 1.8 | NS |
| AF (%) | 19.4 | 21.2 | NS | 4.9 | 5.7 | NS |
| Calcium-channel blockers (%) | 43.1 | 37.1 | NS | 59.8 | 60.8 | NS |
| ACE-inhibitors (%) | 14.6 | 15.2 | NS | 18.3 | 21.8 | NS |
| Angiotensin Receptor Blockers (%) | 44.4 | 34.6 | P<0.05 | 42.7 | 40.7 | NS |
| Nitrates (%) | 8.3 | 9.5 | NS | 28.5 | 26.2 | NS |
| Nicorandil (%) | 4.2 | 4.2 | NS | 23.2 | 19.9 | NS |
| Beta-blockers (%) | 20.8 | 17.7 | NS | 28.9 | 35.3 | P<0.05 |
| Statins (%) | 29.9 | 19.4 | P<0.05 | 57.7 | 59.6 | NS |
| Fibrates (%) | 1.4 | 4.2 | NS | 1.2 | 3.8 | P<0.05 |
| Diuretics (%) | 38.2 | 29.0 | NS | 28.5 | 17.5 | P<0.001 |
| Oral Hypoglycemic Agents (%) | 9.7 | 12.4 | NS | 18.3 | 24.5 | P<0.05 |
| insulin (%) | 6.9 | 4.2 | NS | 10.6 | 9.8 | NS |
| Number of vessels disease (0–3) | 0 | 0 | 0.96±0.96 | 0.95±097 | NS | |
s-Cr, Serum creatinine; BNP, B-type natriuretic peptide; HD & CAPD, Hemodialysis & continuous ambulatory peritoneal dialysis; LVEF, Left ventricular ejection fraction; LVEDP, Left ventricular end-diastolic pressure; LVESVI, Left ventricular end-systolic volume Index; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass graft;AF, Atrial Fibrillation.